The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Sysmex; Takeda
 
Sabine Tejpar
No Relationships to Disclose
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Delcath Systems; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masayuki Kanai
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Yali Liu
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Sabeen Mekan
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Geetha Pudussery
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Yang Qiu
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Scott Kopetz
Stock and Other Ownership Interests - Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; Daiichi Sankyo; EMD Serono; EMD Serono; Genentech; HalioDx; Holy Stone Healthcare; Ipsen; Jacobio; Karyopharm Therapeutics; Lilly; Lutris; Merck; Natera; Navire; Novartis; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)